Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

NCT00689507 is registered in ClinicalTrials.gov with Applied Molecular Evolution as lead sponsor.

NCT NCT00689507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00689507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Applied Molecular Evolution
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2008
Completion date
May 31, 2014
Enrollment
48 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma